Clinical Trial Update: CBD Delivery with the A-Synaptic GT4 Transdermal Delivery System in with Dravet Syndrome And/or Lennox-Gastaut Syndrome [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/Phase 2 study evaluating cannabidiol delivered via the A-Synaptic GT4 transdermal system for Lennox-Gastaut syndr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dravet Syndrome
• Lennox-gastaut Syndrome

Drugs mentioned

• Cannabidiol (cannabidiol)

Snippet

Sponsor: Alexander Rotenberg | Conditions: Lennox-Gastaut Syndrome (LGS), Dravet Syndrome (DS) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING